ReviewMedicina (Kaunas, Lithuania)2020
Update on COVID-19 Myocarditis.
Review in Medicina (Kaunas, Lithuania), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.Journal of infection and public health · 2022Trial
- Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature.Cureus · 2023Review
- Cardiac MRI in patients with COVID-19 infection.European radiology · 2023Article
- Review
- The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic.Cardiovascular drugs and therapy · 2023Review
- COVID-19 Associated Fulminant Myocarditis in a Fully-Vaccinated Female: A Case Report with Clinical Follow-up.Clinical medicine insights. Case reports · 2023Article
- Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis.Frontiers in immunology · 2023Article
- Article
- Severe COVID-19-associated myocarditis with cardiogenic shock - management with assist devices - a case report & review.BMC anesthesiology · 2022Review
- Beta receptor blocker therapy for the elderly in the COVID-19 era.World journal of clinical cases · 2022Review
- Giant cell myocarditis following COVID-19 successfully treated by immunosuppressive therapy.Clinical case reports · 2022Article
- Focal Myocarditis As the First Sign in the Presentation of a COVID-19 Infection: A Case Report.Cureus · 2022Article
- A Case of COVID-19-Induced Delayed-Onset Myocarditis.The American journal of case reports · 2022Article
- Admission vital signs as predictors of COVID-19 mortality: a retrospective cross-sectional study.BMC emergency medicine · 2022Article
- Review
- Review
- Prevalence and Clinical Implications of COVID-19 Myocarditis.Cardiac electrophysiology clinics · 2022Review
- COVID-19 Infection and Incidence of Myocarditis: A Multi-Site Population-Based Propensity Score-Matched Analysis.Cureus · 2022Article
- Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Fulminant Myocarditis: A Review of Contemporary Literature.Medicina (Kaunas, Lithuania) · 2022Review
- The Potential Impact of COVID-19 Virus on the Heart and the Circulatory System.Infection and drug resistance · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) gained worldwide attention at the end of 2019 when it was identified to cause severe respiratory distress syndrome. While it primarily affects the respiratory system, we now have evidence that it affects multiple organ systems in the human body. Cardiac manifestations may include myocarditis, life threatening arrhythmias, acute coronary syndrome, systolic heart failure, and cardiogenic shock. Myocarditis is increasingly recognized as a complication of Coronavirus-19 (COVID-19) and may result from direct viral injury or from exaggerated host immune response. The diagnosis is established similar to other etiologies, and is based on detailed history, clinical exam, laboratory findings and non-invasive imaging studies. When available, cardiac MRI is the preferred imaging modality. Endomyocardial biopsy may be performed if the diagnosis remains uncertain. Current management is mainly supportive with the potential addition of interventions recommended for severe COVID-19 disease, such as remdesivir, steroids, and convalescent plasma. In the setting of cardiogenic shock and refractory, life-threatening arrhythmias that persist despite medical therapy, advanced mechanical circulatory support devices should be considered. Ultimately, early recognition and aggressive intervention are key factors in reducing morbidity and mortality. Our management strategy is expected to evolve further as we learn more about COVID-19 disease and the associated cardiac complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.